How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
|
|
- Caitlin Quinn
- 5 years ago
- Views:
Transcription
1 2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D D i r e c t o r o f E c h o c a r d i o g r a p h y L a b D i r e c t o r o f O p e r a t i o n s, N o n i n v a s i v e C a r d i o l o g y A s s o c i a t e P r o f e s s o r o f M e d i c i n e N e w Y o r k U n i v e r s i t y L a n g o n e M e d i c a l C e n t e r NYU Leon H. Charney Division of Cardiology
2 Disclosures 2 Speakers Bureau Philips, Medtronic NYU Division of Cardiology
3 Treatment Options for Aortic Stenosis 3 Primary indications for surgical treatment of aortic stenosis SEVERE Aortic Stenosis SYMPTOMS Dyspnea, angina, syncope LV FUNCTION Diminished LVEF NYU Division of Cardiology Severe symptomatic AS irrespective of LVEF Severe AS with diminished LVEF irrespective of symptoms
4 Valve Replacement Options for Aortic Stenosis 4 SAVR Surgical Aortic Valve Replacement (Traditional surgical AVR) TAVR Transcatheter Aortic Valve Replacement same as TAVI Transcatheter Aortic Valve Implantation NYU Division of Cardiology
5 TAVR: PRIMARY INDICATIONS (1)Preferred treatment for inoperable patients (ineligible for SAVR) with severe symptomatic aortic stenosis (2)Alternative treatments for patients with severe symptomatic aortic stenosis who have high SAVR risk NYU Division of Cardiology 5
6 History of TAVR 6 It took a decade to translate the TAVR concept from an animal experiment to a human implant it took another decade to validate TAVR concept in clinical trials Proof of TAVR Concept in Animals First TAVR in Humans PARTNERS Trial of TAVR published TAVR is routine clinical practice NYU Division of Cardiology
7 History of TAVR First Human Implantation in Alain Cribier (b. 1945) French Interventional Cardiologist Performed first TAVR in 2002 (Also first to report percutaneous aortic balloon valvuloplasty in 1986) This first human TAVR: (1) Would not meet current standard indication criteria (Patient had bicuspid aortic valve). (2) Was performed in a manner not performed now (It was done using transvenous, transseptal approach across the mitral valve). NYU Division of Cardiology
8 SURGICAL PROSTHETIC VALVE DEVELOPMENT Trained at Bellevue Hospital, now part of NYU Medical Center 1960 Starr-Edwards mechanical valve 1972 Carpentier-Edwards bioprosthetic valve Albert Starr (b in New York) Miles Lowell Edwards ( ) Alain Carpentier (b in Toulouse)
9 SAVR & TAVR VALVE DEVELOPMENT NYU Leon H. Charney Division of Cardiology 9
10 History of TAVR First Animal Implantation in This first animal TAVR: (1) Was the basis for subsequent balloonexpandable Sapien valve used in humans (2) Was performed in the same manner used in humans now (It was done using transarterial retrograde approach). NYU Division of Cardiology
11 TAVR: The First Wave of Valves 11 NYU Leon H. Charney Division of Cardiology
12 TAVR Prostheses Used in United States 12 Edwards Sapien Valves Balloon-expandable bovine pericardial aortic valve prosthesis Medtronic CoreValves Self-expandable porcine pericardial aortic valve prosthesis NYU Division of Cardiology
13 TAVR Prostheses Used in United States 13 Edwards Sapien Valve Anchoring in the aortic annulus Medtronic CoreValve Anchoring in ascending aorta and LVOT. NYU Division of Cardiology
14 TAVR Prostheses Used in United States 14 Video 1 Video 2 Edwards Sapien Valve Balloon Expandable NYU Division of Cardiology Medtronic CoreValve Self Expanding
15 1 st Wave: What We Have Accomplished 15 NYU Leon H. Charney Division of Cardiology
16 SEVERE AORTIC STENOSIS TEE: Transgastric View NYU Leon H. Charney Division of Cardiology 16
17 SEVERE AORTIC STENOSIS Continuous Wave (CW) Doppler Pulsed Wave (PW) Doppler AORTIC VALVE VTI = 134 cm Vmax = 4.3 m/sec Peak/Mean Gradient 74/43 mm Hg LVOT VTI = 24 cm Vmax = 0.8 m/sec Area 3.14 cm 2 Dimensionless Index = 24 / 134 = 0.18 Aortic Valve Area = 0.6 cm 2 NYU Leon H. Charney Division of Cardiology 17
18 SEVERE AORTIC STENOSIS TREATED WITH SAPIEN TAVR NYU Leon H. Charney Division of Cardiology 18
19 SEVERE AORTIC STENOSIS TREATED WITH COREVALVE TAVR NYU Leon H. Charney Division of Cardiology 19
20 Aortic Valve Gradients Pre & Post TAVR 20 Before TAVR (Severe native valve stenosis) After TAVR (Minimal aortic valve gradients) NYU Division of Cardiology
21 TAVR TREATMENT OUTCOMES NATURAL HISTORY Symptomatic Severe AS Mortality 2-year 50% 5-year 80% Prognosis of severe symptomatic stenosis treated medically is abysmal. NYU Leon H. Charney Division of Cardiology 21
22 1 ST WAVE OF TAVR: WHAT ELSE HAVE WE ACCOMPLISHED? Simplified anesthesia management during TAVR INITIAL TAVR EXPERIENCE General anesthesia SUBSEQUNT TAVR EXPERIENCE Moderate sedation Endotracheal intubation No endotracheal intubation TEE guidance TTE guidance NYU Leon H. Charney Division of Cardiology 22
23 NYU Leon H. Charney Division of Cardiology 23
24 NYU TAVR TEAM NYU Leon H. Charney Division of Cardiology 24
25 CoreValve Deployment 26 NYU Leon H. Charney Division of Cardiology
26 CoreValve Deployed 27 NYU Leon H. Charney Division of Cardiology
27 POST TAVR COMPLICATION: VSD + GERBODE DEFECT NYU Leon H. Charney Division of Cardiology 28
28 POST TAVR COMPLICATION: VSD + GERBODE DEFECT NYU Leon H. Charney Division of Cardiology 29
29 POST TAVR COMPLICATION: VSD + GERBODE DEFECT RA LV to RA Gerbode Jet AV AV RV LV to RV VSD Jet NYU Leon H. Charney Division of Cardiology 30
30 POST TAVR COMPLICATION: MEMBRANOUS VSD + GERBODE DEFECT Membranous Septum Frank Gerbode ( ) American Cardiac Surgeon NYU Leon H. Charney Division of Cardiology 31
31 1 ST WAVE TAVR We have accomplished a lot so what s the problem? NYU Division of Cardiology 32
32 PARAVALVULAR AORTIC REGURGITATION POST TAVR Trivial PVL Marked PVL Potential for Hemolytic Anemia Potential for Hemodynamic Compromise NYU Leon H. Charney Division of Cardiology 33
33 PARAVALVULAR AORTIC REGURGITATION POST TAVR No easy way to grade it VARC II Criteria An expert consensus without empiric validation NYU Leon H. Charney Division of Cardiology 34
34 PARAVALVULAR AR POST TAVR EROA BY 3D ECHO NYU Leon H. Charney Division of Cardiology 35
35 PARAVALVULAR AR POST TAVR IMPACT ON SURVIVAL Higher grades of paravalvular AR portend worse prognosis. Even mild paravalvular AR portends worse prognosis. NYU Leon H. Charney Division of Cardiology 36
36 PARAVALVULAR AR POST TAVR IMPACT ON SURVIVAL Moderate/Severe paravalvular AR Mild paravalvular AR NYU Leon H. Charney Division of Cardiology 37
37 PARAVALVULAR AR POST TAVR MECHANISMS Undersized TAVR Valve Meticulous annular sizing pre- TAVR minimizes this risk. Maldeployed TAVR Valve Reposition existing TAVR or do valvuloplasty or place valve-invalve TAVR Excessive Aortic Root Calcium New TAVR prosthesis designs NYU Leon H. Charney Division of Cardiology 38
38 Annular Sizing 39 NYU Leon H. Charney Division of Cardiology
39 Midsystolic Frames NYU Leon H. Charney Division of Cardiology 40
40 1 0 Generation Edwards Sapien 1 0 Generation Medtronic CoreValve NYU Leon H. Charney Division of Cardiology 41
41 TAVR-RELATED AORTIC ROOT MEASUREMENTS Some interventionalists prefer CT measurements of aortic root over echocardiographic measurements because calcifications interfere with echo but not CT imaging. NYU Leon H. Charney Division of Cardiology 42
42 AORTIC ANNULAR SIZING CT Aortic annular perimeter by CT NYU Leon H. Charney Division of Cardiology 43
43 Edwards Sapien & Sapien XT Medtronic CoreValve NYU Leon H. Charney Division of Cardiology 44
44 AORTIC ANNULAR SIZING 3D TEE NYU Leon H. Charney Division of Cardiology 45
45 Post Dilation for TAVR PVL 46 NYU Leon H. Charney Division of Cardiology
46 BALLOON POST DILATATION ACCENTED MEANS OF REDUCING PVL NYU Division of Cardiology 47
47 Valve-in-Valve For TAVR PVL 48 NYU Leon H. Charney Division of Cardiology
48 1 ST COREVALVE MALPOSITIONED >> PARAVALVULAR AR NYU Division of Cardiology 49
49 2 ND COREVALVE PLACED VIV >> NO MORE PARAVALVULAR AR NYU Division of Cardiology 50
50 New Generation of TAVR Valves 51 NYU Leon H. Charney Division of Cardiology
51 NEW WAVE OF TAVR VALVES (1) Repositionable during delivery (2) Special proximal prosthetic skirt design to prevent PVLs NYU Division of Cardiology 52
52 COREVALVE EVOLUT R NYU Leon H. Charney Division of Cardiology 53
53 SAPIEN 3 NYU Leon H. Charney Division of Cardiology 54
54 DIRECT FLOW NYU Leon H. Charney Division of Cardiology 55
55 DIRECT FLOW NYU Leon H. Charney Division of Cardiology 56
56 DIRECT FLOW NYU Leon H. Charney Division of Cardiology 57
57 PORTICO NYU Leon H. Charney Division of Cardiology 58
58 LOTUS NYU Leon H. Charney Division of Cardiology 59
59 LOTUS NYU Leon H. Charney Division of Cardiology 60
60 EDWARDS CENTERA NYU Leon H. Charney Division of Cardiology 61
61 ENGAGER NYU Leon H. Charney Division of Cardiology 62
62 SYMETIS ACUARATE NYU Leon H. Charney Division of Cardiology 63
63 JENA VALVE NYU Leon H. Charney Division of Cardiology 64
64 Older TAVR Designs Newer TAVR Designs NYU Leon H. Charney Division of Cardiology 65
65 Thank You! 66 New York University Medical Center NYU Leon H. Charney Division of Cardiology
TAVR: Echo Measurements Pre, Post And Intra Procedure
2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationTAVR Cases. Disclosures 2/17/2018. February 17, :15 3:30 PM 15 min
31 st Annual State of the Art Echocardiography San Diego, CA February 17, 2018 3:15 3:30 PM 15 min TAVR Cases Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate Professor
More informationEcho Evaluation of a Mitral Valve Prostheses Sunday, February 14, :50 2:10 PM 20 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ Echo Evaluation of a Mitral Valve Prostheses Sunday, February 14, 2016 1:50 2:10 PM 20 min 1 M U H A M E D S A R I Ć, M D, P H D D i r e c t
More informationPercutaneous Therapy for Calcific Mitral Valve Disease
31 st Annual State of the Art Echocardiography San Diego, CA February 18, 2018 5:00 5:15 PM 15 min Percutaneous Therapy for Calcific Mitral Valve Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationEcho Assessment Pre-TAVI
Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial Interest /arrangement or affiliation with the organization(s) listed below Echocardiographic
More informationComments restricted to Sapien and Corevalve 9/12/2016. Disclosures: Core Lab contracts with Edwards Lifesciences, Middlepeak, Medtronic
Para-ValvularRegurgitation post TAVR: Predict, Prevent, Quantitate, Manage Linda D. Gillam, MD, MPH, FACC, FASE Chair, Department of Cardiovascular Medicine Morristown Medical Center/Atlantic Health System
More informationPVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?
Joint Meeting 1 Aortic and Mitral Club Chairpersons: S.Adamopoulos, M. Vavuranakis, L. Michalis, P. Nihoyannopoulos PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration
More informationFederico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC
TAVR: When Things go Wrong Federico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC Disclosures Academic Echo Core Lab Abbott / St Jude Medical Edwards Medtronic
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationDISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.
Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? G. Burkhard Mackensen, MD, PhD, FASE Professor & Chief, Division of Cardiothoracic Anesthesia, Department of Anesthesiology
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationNew Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology
New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor Cardiothoracic Radiology Disclosure I have no disclosure pertinent to this presentation.
More information*Core lab for numerous trials, for which I receive no direct compensation from sponsors.
Rebecca T. Hahn, MD, FACC, FASE Director of Interventional Echo Professor of Medicine Columbia University Company Abbott Vascular Gore&Assoc NaviGATE Medtronic Boston Scientific GE Medical Philips Healthcare
More informationTAVI: Present and Future Perspective
TAVI: Present and Future Perspective Igor F. Palacios, M.D. Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Percutaneous transcatheter
More informationEmergency TAVI: Does It Exist? Is the Risk Higher?
Emergency TAVI: Does It Exist? Is the Risk Higher? Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia APCASH 12 October 2014 Disclosure Statement of
More informationTHE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationSAPIEN 3 Sizing Considerations:
SAPIEN 3 Sizing Considerations: Oversizing, Undersizing, or Volume reduction? John Webb MD St Paul s Hospital University of British Columbia Vancouver Disclosure Statement of Financial Interest Within
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationPacemaker rates Second generation TAVI Devices
Pacemaker rates Second generation TAVI Devices Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany TAVI The future s looking very positive
More informationAndrzej Ochala, MD Medical University of Silesia, Katowice, Poland
Andrzej Ochala, MD Medical University of Silesia, Katowice, Poland Bicuspid aortic valve o Most common congenital heart disease in adults (1% - 2%) o AS is the most common complication of BAV o Patophysiology
More informationPARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR
PARAVALVULAR LEAK POST TAVR David S Rubenson MD FACC FASE Founding Director, Cardiac Non-Invasive Laboratory Scripps Clinic Medical Group number 1 Elements of Follow-up Post TAVR JACC CV Imag 2016;9:193
More informationNouvelles indications/ Nouvelles valves
Nouvelles indications/ Nouvelles valves Sadra Lotus Valve system Boston Scientific A. Tirouvanziam Institut Thorax Nantes SH-31314-AC Sept 2012 Slide 1 of 53 SH-31314-AC Sept 2012 Slide 2 of 53 Building
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationTranscatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee
Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee Queen Elizabeth Hospital, Hong Kong President, HKSTENT APCASH 2013 SJ Park TAVI Summit 2013
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Director, Interventional Cardiology Research, Beaumont Health System Associate Professor of Medicine,
More informationHOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?
HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado
More informationProgress In Transcatheter Aortic Valve Implantation
Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement
More informationTAVR TTE INTERROGATION BY ALAN MATTHEWS
TAVR TTE INTERROGATION BY ALAN MATTHEWS KEYS TO ACCURATE ASSESSMENT EDWARDS SAPIEN VALVE 3 PHASES OF TAVR TTE Evaluation (Qualifying) Placement (Intraoperative) Follow-up (Post-Op) GOALS High quality TTE
More information2/10/2012. The Role of Multimodality Imaging in Percutaneous Valve Interventions. This is truly a TEAM work. Overview. Overview
The Role of Multimodality Imaging in Percutaneous Valve Interventions João L. Cavalcante, MD Advanced Cardiovascular Imaging Cleveland Clinic 02/11/2012 Disclosures: None Movement from surgery to transcatheter
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationParavalvular Regurgitation is a Risk Factor Following TAVI
Paravalvular Regurgitation is a Risk Factor Following TAVI Philippe Pibarot, DVM, PhD, FACC, FESC, FASE Canada Research Chair in Valvular Heart Disease INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationTrans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
More informationMenachem M. Weiner Assistant Professor of Anesthesiology Icahn School of Medicine at Mount Sinai
Menachem M. Weiner Assistant Professor of Anesthesiology Icahn School of Medicine at Mount Sinai Anesthetic care and considerations Intraoperative events TEE Perioperative complications Most common valvular
More informationDisclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience
Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience The LGH TAVR Program James E. Harvey, MD, MSc Medical Director, Structural Heart Intervention The Heart Group of Lancaster
More informationOptimal Imaging Technique Prior to TAVI -Echocardiography-
2014 KSC meeting Optimal Imaging Technique Prior to TAVI -Echocardiography- Geu-Ru Hong, M.D. Ph D Associate Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University
More informationCorrado Tamburino, MD, PhD
Paravalvular leak: acceptable or not Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology Division,
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationtranscatheter heart valve: THV TAVI transcatheter aortic valve implantation
transcatheter heart valve: THV TAVI transcatheter aortic valve implantation Hideki OSHIMA 1. はじめに transcatheter heart valve: THV 1) transcatheter aortic valve implantation: TAVI transcatheter mitral valve
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationAortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationThe Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy
The Future of Medicine Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy FIRST PATIENT TO UNDERGO PTCA FIRST PATIENT TO UNDERGO TAVI Grüntzig
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationTranscatheter Aortic Valve Implantation Management of risks and complications
Transcatheter Aortic Valve Implantation Management of risks and complications TAVI Summit, Seoul, Korea, Spetember 3rd, 2011 Alain Cribier University of Rouen, France Complications of TAVI Depending on
More informationTranscatheter Aortic Valve Replacement with Evolut-R
Transcatheter Aortic Valve Replacement with Evolut-R Department of Transcatheter Heart Valves and 2 nd Cardiothoracic Surgery Clinic K. Spargias, M.Chrissoheris, A.Halapas, I. Nikolaou, S.Pattakos Disclosures
More informationVALVULAR HEART DISEASE AORTIC VALVE STENOSIS TAVR PROCEDURE
CVI SYMPOSIUM 2012 VALVULAR HEART DISEASE AORTIC VALVE STENOSIS TAVR PROCEDURE Luis F. Tami, MD Cardiac Cath Lab Director Memorial Regional Hospital 86 yr old CABG 1995. LIMA to LAD and SVG to OM. Presented
More informationImaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013
Imaging in TAVI Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston Scientific, St Jude, BMS imaging, GE Healthcare,
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationTAVI IN BICUSPID AOV AND VALVE-IN-VALVE
TAVI IN BICUSPID AOV AND VALVE-IN-VALVE Petros S. Dardas, MD, FESC St Lukes Hospital Thessaloniki, GREECE 6o ΣΥΝΕΔΡΙΟ ΔΙΑΚΑΘΕΤΗΡΙΑΚΗΣ ΘΕΡΑΠΕΙΑΣ ΚΑΡΔΙΑΚΩΝ ΒΑΛΒΙΔΟΠΑΘΕΙΩΝ ΑΘΗΝΑ 2017 BICUSPID AOV Surgical
More informationAssessment and Preparation of Patients with TAVI. Rob Tanzola Associate Professor, Queen s University
Assessment and Preparation of Patients with TAVI Rob Tanzola Associate Professor, Queen s University My patient has aortic stenosis and needs non-cardiac surgery Should (s)he get a TAVI? Rob Tanzola Associate
More informationStructural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)
Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR) Kathleen Harper DO FACC FACP 87 Chief, Cardiology Section VA Maine Healthcare Kathleen.Harper@va.gov Prevalence of Aortic Stenosis
More informationHeart Team For TAVI Who and How?
2 nd TAVI Summit 2012, Seoul Corea Heart Team For TAVI Who and How? Alain Cribier, MD, Charles Nicolle Hospital University of Rouen, France Disclosure Edwards Lifesciences Consultant Training / proctoring
More informationTranscatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
More informationTranscatheter Heart Valve Procedures
Medical Coverage Policy Transcatheter Heart Valve Procedures Table of Contents Coverage Policy... 1 Overview... 2 General Background... 2 Coding/Billing Information... 27 References... 29 Effective Date...11/15/2017
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationMinimalist Transcatheter Aortic Valve Replacement (MA-TAVR)
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) Jensen HA, Condado JF, Devireddy C, Binongo JN, Leshnower BG, Babaliaros V, Sarin EL, Lerakis S, Guyton RA, Stewart JP, Syed AQ, Mavromatis K,
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationSuccessful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement
Advanced Studies in Medical Sciences, Vol. 2, 2014, no. 1, 37-45 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/asms.2014.31213 Successful Transfemoral Edwards Sapien Aortic Valve Implantation
More informationWhat will be the TAVI's future? Which developments can we still expect in the forthcoming years?
What will be the TAVI's future? Which developments can we still expect in the forthcoming years? Patrick Serruys, MD, PhD Christos V Bourantas, MD, PhD Yoshinobu Onuma, MD Nicolo Piazza, MD, PhD Nicholas
More informationPotential conflicts of interest
Potential conflicts of interest Speaker's name: Petros Dardas MEDTRONIC proctor for TAVI Intermediate risk 83 FEMALE COAD SEVERE AS NYHA III Mean gradient 35 mmhg, AVA 0.45cm2, SVI 21ml/m2 Paradoxical
More informationΔιαδερμική θεραπεία των παραβαλβιδικών διαφυγών Σ.Ράμμος
ΔΜΙΝΑΡΙΟ ΔΠΙΣΗΜΟΝΙΚΩΝ ΔΝΩΔΩΝ ΔΛΛΗΝΙΚΟΤ ΚΟΛΛΔΓΙΟΤ ΚΑΡ ΙΟΛΟΓΙΑ 2-4.10.2015 Δπιζηημονική Ένωζη Δπεμβαηικής Καρδιολογίας Βαλβιδοπάθειες, Γιαδερμικές παρεμβάζεις Διαδερμική θεραπεία των παραβαλβιδικών διαφυγών
More informationTAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationAre Heart Valve Referral Centers Feasible in Latin America?
Are Heart Valve Referral Centers Feasible in Latin America? Vadim Kotowicz, MD Chief of Cardiovascular Surgery Department Italian Hospital of Buenos Aires Disclosure Medtronic inc. Consultanting Johnson
More informationStress Testing in Valvular Disease
2017 ASE Florida Orlando, FL October 10, 2017 2:40 2:50 PM 10 min Grand Harbor Ballroom South Stress Testing in Valvular Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationRole of Sutureless Valves in the Surgeon s Armamentarium Prof. Dr Malakh Shrestha Vice Chair, Director of Aortic Surgery Cardiothoracic,
Role of Sutureless Valves in the Surgeon s Armamentarium Prof. Dr Malakh Shrestha Vice Chair, Director of Aortic Surgery Cardiothoracic, transplantation and Vascular Surgery Hannover Medical School, Germany
More informationHistory. 2D echo before TAVI. 88 female Hypertensive - hyperlipidemic History of LOC syncope Echo: severe AS AV gradient 90 mmhg Good LV LVH
History 88 female Hypertensive - hyperlipidemic History of LOC syncope Echo: severe AS AV gradient 90 mmhg Good LV LVH 2D echo before TAVI LHC: Normal cors Pre severe calcification LVOT calcification
More informationOutcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
More informationCulprit vs Multivalve Transcatheter Intervention
Culprit vs Multivalve Transcatheter Intervention Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationCardiac catheterisation in AS
AORTIC STENOSIS MANAGEMENT OF VALVULAR AORTIC STENOSIS Dr Badri Paudel Third most common cardiovascular disease Most prevalent valvular heart disease in the world Commonest acquired valvular lesion with
More informationTranscatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital,
Transcatheter aortic valves in aortic regurgitation Gry Dahle Dept of Cardiothoracic- and vascular surgery Rikshospitalet, Oslo University Hospital, Oslo, Norway Aortic regurgitation Prevalence in Framingham
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationProf. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation
Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few
More informationSection 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient
Section 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient Indication 1. Unexplained murmur or abnormal heart sounds 2. Reasonable suspicion of valvular
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationTAVR for Complex Aortic Valvular Conditions
TAVR for Complex Aortic Valvular Conditions Wilson Y. Szeto, MD Professor of Surgery Chief, Cardiovascular Surgery at Penn Presbyterian Surgical Director, Transcatheter Cardio-Aortic Therapies Associate
More informationDISCLOSURE. Relevant Financial Relationship(s) Off Label Usage. None. None
Echo for TAVR Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echocardiography Associate Director, Cardiology Fellowship Mayo
More informationTranscatheter Mitral Valve Replacement How Close Are We?
Transcatheter Mitral Valve Replacement How Close Are We? Gregory Pavlides, MD, PhD, FACC, FESC Professor of Medicine Miscia Chair of Interventional Cardiology Director, Cardiac Catheterization Laboratories,
More information